

高橋 隆

名古屋大学大学院医学系研究科 分子腫瘍学 教授

<略歴>

1954年三重県生まれ。1979年名古屋大学医学部卒業。外科医としての5年間の臨床研修の過程で、がんの本質の理解に根差したブレークスルーの必要性を痛感。名古屋大学医学部胸部外科に帰局直後より愛知県がんセンター研究所でがんの基礎研究を開始。1988年医学博士（名古屋大学）。1988年米国国立がん研究所（NCI）博士研究員。p53遺伝子異常を肺癌において発見。1990年-2004年愛知県がんセンター研究所（分子腫瘍学部・部長）。1993年日本癌学会奨励賞。2004年名古屋大学大学院医学系研究科教授（神経疾患・腫瘍分子医学研究センター・分子腫瘍学分野）。2012年同・センター長。

<専門・研究対象>

肺癌の分子病態をより深く理解すべく、新たな肺癌関連遺伝子・分子標的の同定及び機能解析などの基礎研究から、極めて近未来における臨床への導入を目指したバイオマーカー探索などの応用研究まで、ゲノミクス、プロテオミクス解析を含む実験室におけるウェット解析と、コンピュータを用いたインシリコの解析を統合し、多角的に研究を展開中。

<主な研究実績>

1. Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, Arima C, Kato S, Tomida S, Suzuki M, Osada H, Takahashi T. NKX2-1/TTF1/TTF-1-induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. *Cancer Cell* 21: 348-361, 2012.
2. Hosono Y, Yamaguchi T, Mizutani E, Yanagisawa K, Arima C, Tomida S, Shimada Y, Hiraoka M, Kato S, Yokoi K, Suzuki M, Takahashi T. MYBPH, a transcriptional target of TTF-1, inhibits ROCK1, and reduces cell motility and metastasis. *EMBO J* 31: 481-493, 2012.
3. Nishikawa E, Osada H, Okazaki Y, Arima C, Tomida S, Tatematsu Y, Taguchi A, Shimada Y, Yanagisawa K, Yatabe Y, Toyokuni S, Sekido Y, and Takahashi T. miR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer. *Cancer Res.* 71:6165-6173, 2011.
4. Yanagisawa K, Konishi H, Arima C, Tomida S, Takeuchi T, Shimada Y, Yatabe Y, Mitsudomi T, Osada H, Takahashi T. Novel metastasis-related gene CIM functions in the regulation of multiple cellular stress response pathways. *Cancer Res.* 70:9949-58, 2010.
5. Ebi H, Tomida S, Takeuchi T, Arima C, Sato T, Mitsudomi T, Yatabe Y, Osada H,

Takahashi T. Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses. *Cancer Res.* 69: 4027-2035, 2009

6.Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, Mitsudomi T, Yatabe Y, Takahashi T. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. *J. Clin. Oncol.* 27:2793-2799, 2009.

7.Tokumaru S, Suzuki M, Yamada H, Nagino N, Takahashi T. let-7 regulates Dicer expression and constitutes a negative feedback loop. *Carcinogenesis* 29: 2073-2077, 2008.

8.Taguchi A, Yanagisawa K, Tanaka M, Cao K, Matsuyama Y, Goto H, Takahashi T. Identification of HIF-1 α as a novel target for miR-17-92 microRNA cluster. *Cancer Res.* 68: 5540-5545, 2008.

9.Tanaka H, Yanagisawa K, Shinjo K, Taguchi A, Maeno K, Tomida S, Shimada Y, Osada H, Kosaka T, Matsubara H, Mitsudomi T, Sekido Y, Tanimoto M, Yatabe Y, Takahashi T. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. *Cancer Res.* 67: 6007-6011, 2007.

10.Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, Mitsudomi T, Takahashi T. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. *J. Clin. Oncol.* 24: 1679-1688, 2006.

11.Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Kawahara K, Sekido Y, Takahashi T. A polycistronic miRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. *Cancer Res.* 65: 9628-9632, 2005.

12.Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada T, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. *Cancer Res.* 64: 3753-3756, 2004.

13.Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. *Am. J. Surg. Pathol.* 26: 767-773, 2002.

14.Haruki N, Harano T, Masuda A, Kiyono T, Tatematsu Y, Shimizu S, Mitsudomi T, Konishi H, Osada H, Fujii, Y, Takahashi T. Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation. *Am. J. Pathol.* 159: 1345-1352, 2001.

15.Kozaki K, Miyaishi O, Tsukamoto T, Tatematsu Y, Hida T, Takahashi T, Takahashi T. Establishment and characterization of a human lung cancer cell line NCI-H460-LNM35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic

propagation. *Cancer Res.* 60: 2535-2540, 2000.

16. Nishio M, Koshikawa T, Kuroishi T, Suyama M, Uchida K, Takagi Y, Washimi O, Sugiura T, Ariyoshi Y, Takahashi T, Ueda R, Takahashi T. Prognostic significance of abnormal p53 accumulation in primary, resected non-small cell lung cancers. *J. Clin. Oncol.* 14: 497-502, 1996.

17. Suzuki H, Ueda R, Takahashi T, Takahashi T. Altered imprinting in lung cancer. *Nature Genet.* 6: 332-333, 1994.

18. Takahashi T, Carbone D, Takahashi T, Nau M, Hida T, Linnoila I, Ueda R, Minna J. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. *Cancer Res.* 52: 2340-2343, 1992.

19. Takahashi T, Nau M, Chiba I, Birrer M, Rosenberg R, Vinocour M, Levitt M, Pass H, Gazdar A, Minna J. p53: a frequent target for genetic abnormalities in lung cancer. *Science* 246: 491-494, 1989.

20. Takahashi T, Ueda R, Xiaoshi S, Nishida K, Shinzato M, Namikawa R, Ariyoshi Y, Ota K, Kato K, Nagatsu T, Imaizumi M, Abe T, Takahashi, T. Two novel cell surface antigens on small cell lung carcinoma defined by mouse monoclonal antibodies NE-25 and PE-35. *Cancer Res.* 46: 4770-4775, 1986